Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14712065 | 0.95 | HRH3 (0.45) | HDAC1ALDH1A1HSD11B1HRH3HDAC3 | |
| SCHEMBL3052103 | 0.93 | HDAC1 (0.47) | HDAC1ALDH1A1HSD11B1HRH3SMN1; SMN2 | |
| SCHEMBL3054538 | 0.93 | HDAC1 (0.50) | HDAC1ALDH1A1HRH3SMN1; SMN2MEN1 | |
| SCHEMBL3049424 | 0.91 | HDAC1 (0.51) | HDAC1ALDH1A1HRH3LMNAMAPT | |
| SCHEMBL14712079 | 0.89 | HRH3 (0.49) | HDAC1ALDH1A1HRH3MAPTMAPK1 | |
| SCHEMBL10112796 | 0.89 | OPRM1 (0.51) | HDAC1OPRM1 | |
| SCHEMBL1121038 | 0.89 | HDAC1 (0.53) | HDAC1ALDH1A1HDAC3HDAC7HDAC2 | |
| SCHEMBL15348097 | 0.89 | PDE4A (0.39) | HDAC1ALDH1A1HSD11B1HRH3HDAC3 | |
| SCHEMBL15348333 | 0.88 | HDAC1 (0.39) | HDAC1ALDH1A1HSD11B1HRH3HDAC3 | |
| Hydrochloric Acid SCHEMBL23535437 | 0.87 | OPRM1 (0.50) | HDAC1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688741-A1 | COMPOUNDS FOR TREATING FIBROTIC DISEASES | Meta-Immune, Inc. (KR) | 2026-02-11 | — | — | EP | disclosed |
| US-12435128-B2 | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-10-07 | — | — | US | disclosed |
| US-12377083-B2 | Lysophosphatidic acid receptor antagonist and preparation method therefor | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2025-08-05 | — | — | US | disclosed |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| WO-2025050125-A1 | SUBSTITUTED BENZOXAZOLYLAMINO BENZOXAZOLES | IMMVENTION THERAPEUTIX (US) | 2025-03-06 | — | — | WO | disclosed |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | ARDELYX, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| WO-2024249867-A1 | COMPOUNDS FOR TREATING FIBROTIC DISEASES | AM SCIENCES (KR) | 2024-12-05 | — | — | WO | disclosed |
| US-12145924-B2 | Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds | ELI LILLY AND COMPANY (US) | 2024-11-19 | — | — | US | disclosed |
| CN-118290357-A | Heterocyclic compounds useful in the treatment of disease | 艾匹根生物技术有限公司 | 2024-07-05 | — | — | CN | disclosed |
| US-11981661-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-05-14 | — | — | US | disclosed |
| US-7148226-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-20060189681-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | AGOURON PHARMACEUTICALS, INC. | 2006-08-24 | — | — | US | disclosed |
| US-20050282858-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2005-12-22 | — | — | US | disclosed |
| WO-2005110992-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2005-11-24 | — | — | WO | disclosed |
| EP-1597246-A2 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2005-11-23 | — | — | EP | disclosed |
| US-20050234238-A1 | 8-(Biaryl)quinoline pde4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2005-10-20 | — | — | US | disclosed |
| US-20050176701-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2005-08-11 | — | — | US | disclosed |
| EP-1517895-A1 | 8-(BIARYL) QUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2005-03-30 | — | — | EP | disclosed |
| WO-2004074270-A2 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004000814-A1 | 8-(BIARYL) QUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12377083-B2 | Lysophosphatidic acid receptor antagonist and preparation method therefor | LPAR1, LPAR2, LPAR4 | HDAC1 1653/4885ALDH1A1 2782/4885HSD11B1 947/4885 |
| US-12435128-B2 | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 | INMT, CARM1, KDM1B | HDAC1 109/4885ALDH1A1 1178/4885HSD11B1 2524/4885 |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | NR1H4, FXR1, GLP1R | HDAC1 948/4885ALDH1A1 2057/4885HSD11B1 290/4885 |
| US-11981661-B2 | Heterocyclic compounds | CBR3, BRIX1, CCNY | HDAC1 1038/4885ALDH1A1 1218/4885HSD11B1 1433/4885 |
| US-12145924-B2 | Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds | LPAR1, LPAR2, LPAR5 | HDAC1 1204/4885ALDH1A1 2519/4885HSD11B1 1032/4885 |
| US-20050282858-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | HDAC1 727/4885ALDH1A1 311/4885HSD11B1 1/4885 |
| US-20050234238-A1 | 8-(Biaryl)quinoline pde4 inhibitors | IL4, PDE4A, PDE4C | HDAC1 2468/4885ALDH1A1 1085/4885HSD11B1 804/4885 |
| US-20060189681-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | RNASE1, RNASEH1, NSUN3 | HDAC1 357/4885ALDH1A1 322/4885HSD11B1 426/4885 |
| US-20050176701-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | RNASE1, RNASEH1, NSUN3 | HDAC1 357/4885ALDH1A1 322/4885HSD11B1 426/4885 |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | HDAC1 948/4885ALDH1A1 2057/4885HSD11B1 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.